Isolated atrial amyloidosis from atrial natriuretic peptide – a common but overlooked cardiac condition

Keywords: Cardiac amyloidosis, localized amyloidosis, atrial fibrillation, cardiac insufficiency, fibrosis

Abstract

Interest in the misfolding and aggregation of human proteins into amyloid fibrils has increased dramatically in recent years. The systemic amyloidoses constitute a group of serious disorders that often affect the heart. Each systemic amyloid type is derived from one of several plasma proteins, most commonly immunoglobulin light chains or transthyretin. Rapid progress has been made in developing effective treatments for several systemic forms.

There is also growing evidence that localized amyloids – such as those found in the brain or in the islets of Langerhans – or their smaller prefibrillar aggregates can exert toxic effects on nearby cells. However, other localized amyloids remain insufficiently understood. Isolated atrial amyloid (IAA) is derived from the polypeptide hormone atrial natriuretic peptide (ANP), which is expressed by atrial cardiomyocytes. IAA is a common age-related amyloidosis, affecting the left atrium more frequently than the right, with highly variable prevalence reported across studies.

The pathogenesis of IAA is unknown, although increased local concentrations of the precursor polypeptide are typically important in other hormone-derived amyloid disorders. IAA is suspected to contribute to the development of atrial fibrillation, but its potential mechanisms remain unclear and have been difficult to investigate due to the lack of methods for visualizing deposits in vivo. This paper, which provides an overview of the current research on IAA, highlights key gaps in knowledge and proposes approaches for studying IAA in vivo.

Downloads

Download data is not yet available.

References


1.
Cornwell GG III, Westermark P. Senile amyloidosis: a protean manifestation of the aging process. J Clin Pathol. 1980;33:1146–52. doi: 10.1136/jcp.33.12.1146


2.
Soyka J. Ueber die amyloide Degeneration. Prag Med Wschr. 1876;1:165–71.


3.
Pomerance A, Slavin G, McWatt J. Experience with the sodium sulphate-Alcian Blue stain for amyloid in cardiac pathology. J Clin Path. 1976;29:22–6. doi: 10.1136/jcp.29.1.22


4.
Hodkinson HM, Pomerance A. The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. Q J Med. 1977;46:381–7.


5.
Westermark P, Johansson B, Natvig JB. Senile cardiac amyloidosis: evidence of two different amyloid substances in the ageing heart. Scand J Immunol. 1979;10:303–8. doi: 10.1111/j.1365-3083.1979.tb01355.x


6.
Pitkänen P, Westermark P, Cornwell GGI. Senile systemic amyloidosis. Am J Path. 1984;117:391–9.


7.
Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA. 1990;87:2843–5. doi: 10.1073/pnas.87.7.2843


8.
Buxbaum JN, Eisenberg DS, Fändrich M, McPhail ED, Merlini G, Saraiva MJM, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024;31:249–56. doi: 10.1080/13506129.2024.2405948


9.
Kisch B. The sarcosomes of the heart. J Biophys Biochem Cytol. 1956;2:361–2. doi: 10.1083/jcb.2.4.361


10.
Sonnenberg H, Cupples WA, de Bold AJ, Veress AT. Intrarenal localization of the natriuretic effect of cardiac atrial extract. Can J Physiol Pharmacol. 1982;60:1149–52. doi: 10.1139/y82-166


11.
de Bold AJ, Salerno TA. Natriuretic activity of extracts obtained from hearts of different species and from various rat tissues. Can J Physiol Pharmacol. 1983;61:127–30. doi: 10.1139/y83-018


12.
Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17:698–717. doi: 10.1038/s41569-020-0381-0


13.
Kambayashi Y, Nakao K, Mukoyama M, Saito Y, Ogawa Y, Shiono S, et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. 1990;259:341–5. doi: 10.1016/0014-5793(90)80043-I


14.
Oikawa S, Imai M, Ueno A, Tanaka S, Noguchi T, Nakazato H, et al. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature. 1984;309:724–6. doi: 10.1038/309724a0


15.
Thibault G, Garcia R, Gutkowska J, Bilodeau J, Lazure C, Seidah NG, et al. The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. Biochem J. 1987;241:265–72. doi: 10.1042/bj2410265


16.
Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 2000;97:8525–9. doi: 10.1073/pnas.150149097


17.
Meleagros L, Ghatei MA, Gibbs JS, Bloom SR. Pro-atrial natriuretic peptide (1–98): the circulating cardiodilatin in man. Peptides. 1989;10:545–50. doi: 10.1016/0196-9781(89)90140-X


18.
Haller BGD, Zust H, Shaw S, Gnädinger NP, Uehlinger DE, Weidmann P. Effects of posture and ageing on circulating atrial natriuretic peptide levels in man. J Hypertension. 1987;5:551–6. doi: 10.1097/00004872-198710000-00007


19.
Creager MA, Hirsch AT, Nabel EG, Cutler SS, Colucci WS, Dzau VJ. Responsiveness of atrial natriuretic factor to reduction in right atrial pressure in patients with chronic congestive heart failure. J Am Coll Cardiol. 1988;11:1191–8. doi: 10.1016/0735-1097(88)90281-1


20.
de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996;31:7–18. doi: 10.1016/S0008-6363(95)00121-2


21.
Tuinenburg AE, Brundel BJ, Van Gelder IC, Henning RH, Van Den Berg MP, Driessen C, et al. Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. J Cardiovasc Electrophysiol. 1999;10:827–35. doi: 10.1111/j.1540-8167.1999.tb00263.x


22.
Westermark P. Amyloid and polypeptide hormones: what is their inter-relationship? Amyloid. 1994;1:47–60. doi: 10.3109/13506129409148624


23.
Westermark P, Johnson KH. The polypeptide hormone-derived amyloid forms: nonspecific alterations or signs of abnormal peptide-processing? APMIS. 1988;96:475–83. doi: 10.1111/j.1699-0463.1988.tb05332.x


24.
Colombat M, Barres B, Renaud C, Ribes D, Pericard S, Camus M, et al. Mass spectrometry-based proteomic analysis of parathyroid adenomas reveals PTH as a new human hormone-derived amyloid fibril protein. Amyloid. 2021;28:153–7. doi: 10.1080/13506129.2021.1885023


25.
Sletten K, Westermark P, Natvig JB. Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid. J Exp Med. 1976;143:993–8. doi: 10.1084/jem.143.4.993


26.
Kaye GC, Butler MG, D´Ardenne AJ, Edmondson SJ, Camm AJ, Slavin G. Isolated atrial amyloid contains atrial natriuretic peptide: a report of six cases. Br Heart J. 1986;56:317–20. doi: 10.1136/hrt.56.4.317


27.
Johansson B, Wernstedt C, Westermark P. Atrial natriuretic peptide deposited as atrial amyloid fibrils. Biochem Biophys Res Commun. 1987;148:1087–92. doi: 10.1016/S0006-291X(87)80243-7


28.
Linke RP, Voigt C, Störkel FS, Eulitz M. N-terminal amino acid sequence analysis indicates that isolated atrial amyloid is derived from atrial natriuretic peptide. Virchows Arch B. 1988;55:125–7. doi: 10.1007/BF02896569


29.
Pucci A, Wharton J, Arbustini E, Grasso M, Diegoli M, Needleman P, et al. Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity. J Pathol. 1991;165:235–41. doi: 10.1002/path.1711650307


30.
Linke RP, Klein HO, Modrow S, Marin-Grez M. Isolated atrial amyloid deposits. Immunochemical evidence for the presence of polypeptides with molecular weights higher and lower than atrial natriuretic peptide ANP. In: Natvig JB, Förre Ö, Husby G, Husebekk A, Skogen B, Sletten K, et al., eds. Amyloid and amyloidosis 1990. Dordrecht: Kluwer Academic Publisher; 1991. pp. 466–9.


31.
Louros NN, Iconomidou VA, Tsiolaki PL, Chrysina ED, Baltatzis GE, Patsouris ES, et al. An N-terminal pro-atrial natriuretic peptide (NT-proANP) ’aggregation-prone’ segment involved in isolated atrial amyloidosis. FEBS Lett. 2014;588:52–7. doi: 10.1016/j.febslet.2013.10.049


32.
Tzotzos S, Doig AJ. Amyloidogenic sequences in native protein structures. Protein Sci. 2010;19:327–48. doi: 10.1002/pro.314


33.
Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148:1188–203. doi: 10.1016/j.cell.2012.02.022


34.
Lansbury Jr PT. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA. 1999;96:3342–4. doi: 10.1073/pnas.96.7.3342


35.
Lundmark K, Westermark GT, Nyström S, Murphy CL, Solomon A, Westermark P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA. 2002;99:6979–84. doi: 10.1073/pnas.092205999


36.
Walker LC, Schelle J, Jucker M. The prion-like properties of amyloid-β assemblies: implications for Alzheimer’s disease. Cold Spring Harb Perspect Med. 2016;6:a024398. doi: 10.1101/cshperspect.a024398


37.
Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils – a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther. 2014;6:16. doi: 10.1186/alzrt246


38.
Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a009399. doi: 10.1101/cshperspect.a009399


39.
Milardi D, Gazit E, Radford SE, Xu Y, Gallardo RU, Caflisch A, et al. Proteostasis of islet amyloid polypeptide: a molecular perspective of risk factors and protective strategies for type ii diabetes. Chem Rev. 2021;121:1845–93. doi: 10.1021/acs.chemrev.0c00981


40.
Johansson B, Westermark P. The relation of atrial natriuretic factor to isolated atrial amyloid. Exp Mol Pathol. 1990;52:266–78. doi: 10.1016/0014-4800(90)90068-O


41.
Broggini L, Piccoli M, Chaves-Sanjuan A, Bonnet DMV, Cirillo F, Visentin C, et al. Structural characterization of atrial natriuretic peptide amyloid fibrils from patients with atrial fibrillation. Nat Commun. 2025;16:9556. doi: 10.1038/s41467-025-64618-1


42.
Millucci L, Paccagnini E, Ghezzi L, Bernardini G, Braconi D, Laschi M, et al. Different factors affecting human ANP amyloid aggregation and their implications in congestive heart failure. PLoS One 2011. 2011;6:e21870. doi: 10.1371/journal.pone.0021870


43.
Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. Am J Med. 1983;75:618–23. doi: 10.1016/0002-9343(83)90443-6


44.
Röcken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002;106:2091–7. doi: 10.1161/01.CIR.0000034511.06350.DF


45.
Steiner I. The prevalence of isolated atrial amyloid. J Path. 1987;153:395–8. doi: 10.1002/path.1711530413


46.
Looi L-M. Isolated atrial amyloidosis. A clinicopathologic study indicating increased prevalence in chronic heart disease. Hum Pathol. 1993;24:602–7. doi: 10.1016/0046-8177(93)90239-D


47.
Kawamura S, Takahashi M, Ishihara T, Uchino F. Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts. Pathol Int. 1995;45:335–42. doi: 10.1111/j.1440-1827.1995.tb03466.x


48.
Steiner I, Hájková P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Path. 2006;15:287–90. doi: 10.1016/j.carpath.2006.01.005


49.
Yang K, Li CC, Li JH, Zhao SH. Isolated left atrial amyloidosis: masquerading as a left atrial mass. Eur Heart J Cardiovasc Imaging. 2023;24:e30. doi: 10.1093/ehjci/jeac234


50.
Brownell D, Pillai AJ, Nair N. Cardiac amyloidosis: a contemporary review of medical and surgical therapy. Curr Cardiol Rev. 2024;20:72–81. doi: 10.2174/011573403X240302230925043500


51.
Tana M, Tana C, Guglielmi MD, Stefanelli A, Mantini C, Porreca E. Current perspectives on atrial amyloidosis: a narrative review. Rev Cardiovasc Med. 2024;25:73. doi: 10.31083/j.rcm2502073


52.
Kawano H, Ueki N, Senoo A, Matsumaru I, Ohno C, Yoshimuta T, et al. Isolated atrial amyloidosis in a patient with aortic regurgitation and paroxysmal atrial fibrillation. Intern Med. 2025;64:2574–80. doi: 10.2169/internalmedicine.5049-24


53.
Kancerek J, Zniszczoł Ł, Lewandowski P, Wojnicz R. Multimodal diagnosis of cardiac amyloidosis: integrating imaging, histochemistry, and proteomics of precise typing. Int J Mol Sci. 2026;27:820. doi: 10.3390/ijms27020820


54.
Petzl AM, Oranefo J, Oraii A, Riley M, Lin D, Kumareswaran R, et al. Outcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias. Heart Rhythm O2. 2025;6:1088–96. doi: 10.1016/j.hroo.2025.05.008


55.
Störkel S, Bohl J, Schneider H-M. Senile amyloidosis: principles of localization in a heterogeneous form of amyloidosis. Virchows Arch. 1983;44:145–61. doi: 10.1007/BF02890166


56.
Okada A, Kakuta T, Tadokoro N, Tateishi E, Morita Y, Kitai T, et al. Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up. BMC Cardiovasc Disord. 2023;23:281. doi: 10.1186/s12872-023-03319-3


57.
Eldhagen P, Tzortzakakis A, Lund LH, Söderström S, Berg S, Westermark P, et al. Cardiac amyloidosis after lumbar spinal stenosis surgery – a comprehensive prospective cohort study. Amyloid. 2025;32:218–25. doi: 10.1080/13506129.2025.2481310


58.
Yang G, Xiong S, Luo Y, Luo D, Shehata M, Zhang Z, et al. The relative voltage index: a novel tailored method to identify left atrial low voltage areas in non-paroxysmal AF. Front Cardiovasc Med. 2025;12:1656983. doi: 10.3389/fcvm.2025.1656983


59.
Liutkute A, Berrandou TE, Kestel S, Schnelle M, Dschun O, Amedei HA, et al. Mass spectrometric proteome profiling using a deep spectral library reveals homogenization of right and left atrial proteomes in persistent atrial fibrillation patients. Cardiovasc Res. 2026;cvag076. doi: 10.1093/cvr/cvag076


60.
Steiner I, Hájková P, Kvasnicka J, Kholová I. Myocardial sleeves of pulmonary veins and atrial fibrillation: a postmortem histopathological study of 100 subjects. Virchows Arch. 2006;449:88–95. doi: 10.1007/s00428-006-0197-2


61.
Johansson B, Westermark P. Isolated atrial amyloidosis. Increased frequency in patients with congestive cardiac failure. In: Natvig JB, Førre Ø, Husby G, Husebekk A, Skogen B, Sletten K, et al., eds. Amyloid and amyloidosis 1990. Dordrecht: Kluwer; 1991, pp. 474–6.


62.
Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll Cardiol. 2019;73:1733–4. doi: 10.1016/j.jacc.2019.01.035


63.
Makino M, Moriwaki K, Fujimoto N, Kirii Y, Mizutani H, Goto T, et al. Vanishing left atrial mass in a middle-aged woman: spontaneous intramural left atrial hematoma in isolated atrial amyloidosis. Circ Cardiovasc Imaging. 2024;17:e016905. doi: 10.1161/CIRCIMAGING.124.016905


64.
Thelander U, Westermark GT, Antoni G, Estrada S, Zancanaro A, Ihse E, et al. Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. Int J Cardiol. 2022;352:84–91. doi: 10.1016/j.ijcard.2022.01.036


65.
Schöppenthau D, Schatka I, Berger A, Pieske B, Hahn K, Knebel F, et al. Isolated atrial amyloidosis suspected by electrophysiological voltage mapping and diagnosed by (99m) Tc-DPD scintigraphy. ESC Heart Fail. 2020;7:4305–10. doi: 10.1002/ehf2.12964


66.
Manole S, Pintican R, Budurea C, Pop S, Iancu SD, Popa L, et al. Increased left ventricular mass index and atrial volume index are associated with atrial fibrosis in patients with atrial fibrillation. J Clin Med. 2025;14:6432. doi: 10.3390/jcm14186432


67.
Pucci A, Aimo A, Musetti V, Barison A, Vergaro G, Genovesi D, et al. Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. J Am Heart Assoc. 2021;10:e020358. doi: 10.1161/JAHA.120.020358
Published
2026-06-12
How to Cite
Westermark , P., Wikström , G., & Eldhagen , P. (2026). Isolated atrial amyloidosis from atrial natriuretic peptide – a common but overlooked cardiac condition. Upsala Journal of Medical Sciences, 131, e14458. https://doi.org/10.48101/ujms.v131.14458